These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Bcl-xL is phosphorylated in malignant cells following microtubule disruption. Poruchynsky MS; Wang EE; Rudin CM; Blagosklonny MV; Fojo T Cancer Res; 1998 Aug; 58(15):3331-8. PubMed ID: 9699663 [TBL] [Abstract][Full Text] [Related]
3. Taxol and estramustine-induced modulation of human prostate cancer cell apoptosis via alteration in bcl-xL and bak expression. Liu QY; Stein CA Clin Cancer Res; 1997 Nov; 3(11):2039-46. PubMed ID: 9815595 [TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. Walczak H; Bouchon A; Stahl H; Krammer PH Cancer Res; 2000 Jun; 60(11):3051-7. PubMed ID: 10850456 [TBL] [Abstract][Full Text] [Related]
5. "Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis. Fang G; Chang BS; Kim CN; Perkins C; Thompson CB; Bhalla KN Cancer Res; 1998 Aug; 58(15):3202-8. PubMed ID: 9699642 [TBL] [Abstract][Full Text] [Related]
6. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Zangemeister-Wittke U; Leech SH; Olie RA; Simões-Wüst AP; Gautschi O; Luedke GH; Natt F; Häner R; Martin P; Hall J; Nalin CM; Stahel RA Clin Cancer Res; 2000 Jun; 6(6):2547-55. PubMed ID: 10873111 [TBL] [Abstract][Full Text] [Related]
7. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Henkels KM; Turchi JJ Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248 [TBL] [Abstract][Full Text] [Related]
8. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Liu JR; Fletcher B; Page C; Hu C; Nunez G; Baker V Gynecol Oncol; 1998 Sep; 70(3):398-403. PubMed ID: 9790794 [TBL] [Abstract][Full Text] [Related]
9. Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Ibrado AM; Huang Y; Fang G; Liu L; Bhalla K Cancer Res; 1996 Oct; 56(20):4743-8. PubMed ID: 8840993 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of bcl-2 or bcl-XL fails to inhibit apoptosis mediated by a novel retinoid. Fontana JA; Sun RJ; Rishi AK; Dawson MI; Ordónez JV; Zhang Y; Tschang SH; Bhalla K; Han Z; Wyche J; Poirer G; Sheikh MS; Shroot B; Reichert U Oncol Res; 1998; 10(6):313-24. PubMed ID: 9848102 [TBL] [Abstract][Full Text] [Related]
11. Bcl-xL promotes metastasis of breast cancer cells by induction of cytokines resistance. Fernández Y; España L; Mañas S; Fabra A; Sierra A Cell Death Differ; 2000 Apr; 7(4):350-9. PubMed ID: 10773819 [TBL] [Abstract][Full Text] [Related]
12. Effects of Bcl-2 and Bcl-XL protein levels on chemoresistance of hepatoblastoma HepG2 cell line. Luo D; Cheng SC; Xie H; Xie Y Biochem Cell Biol; 2000; 78(2):119-26. PubMed ID: 10874473 [TBL] [Abstract][Full Text] [Related]
13. Antisense RNA down-regulation of bcl-xL Expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents. Vilenchik M; Raffo AJ; Benimetskaya L; Shames D; Stein CA Cancer Res; 2002 Apr; 62(7):2175-83. PubMed ID: 11929841 [TBL] [Abstract][Full Text] [Related]
14. Enforced expression of Bcl-XS induces differentiation and sensitizes chronic myelogenous leukemia-blast crisis K562 cells to 1-beta-D-arabinofuranosylcytosine-mediated differentiation and apoptosis. Ray S; Bullock G; Nuñez G; Tang C; Ibrado AM; Huang Y; Bhalla K Cell Growth Differ; 1996 Dec; 7(12):1617-23. PubMed ID: 8959329 [TBL] [Abstract][Full Text] [Related]
15. Bcl-xL overexpression restricts heat-induced apoptosis and influences hsp70, bcl-2, and Bax protein levels in FL5.12 cells. Robertson JD; Datta K; Kehrer JP Biochem Biophys Res Commun; 1997 Dec; 241(1):164-8. PubMed ID: 9405251 [TBL] [Abstract][Full Text] [Related]
16. Genomic profiling of acquired resistance to apoptosis in cells derived from human atherosclerotic lesions: potential role of STATs, cyclinD1, BAD, and Bcl-XL. Gagarin D; Yang Z; Butler J; Wimmer M; Du B; Cahan P; McCaffrey TA J Mol Cell Cardiol; 2005 Sep; 39(3):453-65. PubMed ID: 16005468 [TBL] [Abstract][Full Text] [Related]
17. Bcl-XL induction during terminal differentiation of friend erythroleukaemia cells correlates with delay of apoptosis and loss of proliferative capacity but not with haemoglobinization. Hafid-Medheb K; Poindessous-Jazat V; Augery-Bourget Y; Hanania N; Robert-Lézénès J Cell Death Differ; 1999 Feb; 6(2):166-74. PubMed ID: 10200563 [TBL] [Abstract][Full Text] [Related]
18. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells. Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076 [TBL] [Abstract][Full Text] [Related]
19. Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Dole MG; Jasty R; Cooper MJ; Thompson CB; Nuñez G; Castle VP Cancer Res; 1995 Jun; 55(12):2576-82. PubMed ID: 7780971 [TBL] [Abstract][Full Text] [Related]
20. Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity. Tirado OM; Mateo-Lozano S; Notario V Oncogene; 2005 May; 24(20):3348-57. PubMed ID: 15782132 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]